08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

BioReliance, Sigma-Aldrich deal

Sigma-Aldrich completed its acquisition of CRO BioReliance from private equity firm Avista Capital Partners for $350 million in cash. BioReliance will become part of Sigma-Aldrich's SAFC custom manufacturing and services business unit (see BioCentury, Jan....
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

BioReliance Holdings Inc., Sigma-Aldrich deal

Private equity firm Avista Capital Partners agreed to sell CRO BioReliance to Sigma-Aldrich for $350 million in cash. Sigma-Aldrich said BioReliance recorded 2010 revenues of about $110 million. BioReliance provides biopharma testing services, including biologics...
01:53 , Jan 10, 2012 |  BC Extra  |  Company News

Avista selling CRO BioReliance to Sigma-Aldrich

Private equity firm Avista Capital Partners will sell CRO BioReliance Corp. (Rockville, Md.) to Sigma-Aldrich Corp. (NASDAQ:SIAL) for $350 million in cash. Sigma-Aldrich said BioReliance recorded 2010 revenues of about $110 million. The deal is...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Itero board of directors update

Itero Biopharmaceuticals Inc. , San Mateo, Calif.   Business: Biopharmaceuticals   Appointed: Charles Harwood, a director at BioReliance Corp. ; Michael Ross, managing partner at SV Life Sciences; Bobba Venkatadri, general partner at VenturEast; and...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Company News

BioReliance management update

BioReliance Corp. , Rockville, Md.   Business: Supply/Service   Hired: James Kramer as VP of operations for U.S. biologics, formerly SVP and general manager at Talecris Biotherapeutics' Talecris Plasma Resources division  ...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

BioReliance, Gentronix sales and marketing update

BioReliance launched the GreenScreen HC in vitro assay to detect genotoxic agents. The test was developed by Gentronix. BioReliance Corp. , Rockville, Md.   Gentronix Ltd. , Manchester, U.K.   Business: Supply/Service  ...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Invitrogen, Viropro, Avista Capital Holdings L.P. deal

IVGN and VPRO will combine VPRO’s protein production technology with IVGN’s PD Direct media and cell line development technology to develop a technology for manufacturing MAbs. VPRO will own the resulting technology. Further terms were...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

Invitrogen, Avista Capital Holdings L.P. deal

IVGN sold its BioReliance Corp. contract research business unit to private equity firm Avista for $210 million. IVGN acquired BioReliance, which provides biological safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services, for $500...
08:00 , Feb 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

When Invitrogen bought BioReliance for $500 million in cash in early 2004, the rationale was clear: make a bioproduction powerhouse by coupling services with products. The deal combined IVGN's media, sera, reagents, packaging and cell...
08:00 , Feb 19, 2007 |  BioCentury  |  Finance

EPS watch

EPS watch Company 4Q06EPS est 4Q06 EPS actual Outcome Growth from 4Q05 2/16 cls Wk chg % chg Mcap chg 2/16 Mcap Biogen Idec (BIIB) $0.55 $0.53 Missed by $0.02 10% $48.25 -$1.25 -3% -$423.2...